2026 Q2 - tulosraportti
76 päivää sitten
‧48 min
1,00 NOK/osake
Viimeisin osinko
33,44%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 2 908 | ||
| 2 876 | ||
| 3 675 | ||
| 7 946 | ||
| 42 054 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·4 min sitten · MuokattuModerna continues to rise! 🚀 Yesterday the stock rose 5.83 %, it continues up in the pre-market today, and is now up a whopping 21.81 % the last week. Looking back three months, the increase is an incredible 354.62 %! The market is clearly positioning itself ahead of what could be a very important update. Thursday November 12, Moderna is holding its long-discussed R&D Day, where management is expected to present new, important data and updated timelines for the company's future pipeline. We surely all remember what happened last time Moderna came with a major update to the market? 😉 Could it be set for new movements in the biotech sector? And perhaps worth paying a little extra attention to what this could mean for companies like Nykode? Much exciting happening in the sector right now. And speaking of exciting days in biotech: Nykode is actually also participating at Guggenheim Securities 3rd Annual Healthcare Innovation Conference today! There they will present the company's progress and discuss key value drivers, among others abi-suva, VB10.NEO and the company's immunological tolerance platform. So it is more than just a general investor conference. Management will speak concretely about progress and value drivers.
·2 t sittenI advise everyone to opt out of share lending. 1. Log in to Nordnet. 2. Click on Menu. 3. Select My Pages. 4. Open Settings. 5. Find Share Lending (Share Lending). 6. Click End participation / Deactivate share lending. 7. Confirm with BankID if prompted. 8. Verify that the status shows Not active or Not participant. If Share Lending is not found in the menu, you are likely not participating in the scheme.
·21 t sittenJust for fun, laying in the charts for Nykode, Nanexa and Moderna, all with 3 years development. If Nykode follows, it could get fun here 🙂🙂🙂
Yes it is allowed to hope, and the graph shows enormous upside if they hit on the development of medicines. That is also the reason why the shares are priced low now, because it is not certain that they hit. But like you I hope this hits and reaches the same heights as moderna:)- ·6.11. · MuokattuWorth bringing up this Finansavisen article from last week again: "Healthcare stocks become investors' anti-AI bet". Nervous investors are seeking refuge in the healthcare sector. With the sharp fall we are now seeing in the AI and tech sector in the US, this article becomes extra interesting. When AI and tech stocks lose momentum, we can see a rotation where investors to a greater extent seek towards other sectors – and not least healthcare and biotechnology. The article is already showing signs of this development. American healthcare funds have attracted around 4 billion dollars over 65 trading days, while technology funds in the same period have had outflows of around 6 billion dollars. Healthcare has long stood somewhat in the shadow of the AI hype. Perhaps now is the sector gets its long-awaited renaissance? It would at least be fitting if Nykode also got some of this attention! 😉 https://www.finansavisen.no/helse/2026/10/27/8390924/helseaksjer-blir-investorenes-anti-ai-veddemalGood to keep in mind that teq stocks have risen 100-200% in a short time, which has helped the market upwards in other sectors. When and if margin calls start to hurt in teq, the rest of the market is used as an ATM, meaning that stocks are sold where they necessarily do not want to sell but have to! Pharma is strongly represented there. The first to go are bets (bioteq where it is not clarified), then the safe havens. I am not saying that nykode is one of them, but one should have a portion of risk management in these times.
5.11.Nykode Therapeutics to Participate in Fireside Chat at the Guggenheim 3rd Annual Healthcare Innovation Conference https://newsweb.oslobors.no/message/685712
Hoping representatives from Eli Lilly are also there and buy the whole joint for kr 10 per share. Allowed to dream 🤭
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
76 päivää sitten
‧48 min
1,00 NOK/osake
Viimeisin osinko
33,44%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·4 min sitten · MuokattuModerna continues to rise! 🚀 Yesterday the stock rose 5.83 %, it continues up in the pre-market today, and is now up a whopping 21.81 % the last week. Looking back three months, the increase is an incredible 354.62 %! The market is clearly positioning itself ahead of what could be a very important update. Thursday November 12, Moderna is holding its long-discussed R&D Day, where management is expected to present new, important data and updated timelines for the company's future pipeline. We surely all remember what happened last time Moderna came with a major update to the market? 😉 Could it be set for new movements in the biotech sector? And perhaps worth paying a little extra attention to what this could mean for companies like Nykode? Much exciting happening in the sector right now. And speaking of exciting days in biotech: Nykode is actually also participating at Guggenheim Securities 3rd Annual Healthcare Innovation Conference today! There they will present the company's progress and discuss key value drivers, among others abi-suva, VB10.NEO and the company's immunological tolerance platform. So it is more than just a general investor conference. Management will speak concretely about progress and value drivers.
- ·2 t sittenI advise everyone to opt out of share lending. 1. Log in to Nordnet. 2. Click on Menu. 3. Select My Pages. 4. Open Settings. 5. Find Share Lending (Share Lending). 6. Click End participation / Deactivate share lending. 7. Confirm with BankID if prompted. 8. Verify that the status shows Not active or Not participant. If Share Lending is not found in the menu, you are likely not participating in the scheme.
- ·21 t sittenJust for fun, laying in the charts for Nykode, Nanexa and Moderna, all with 3 years development. If Nykode follows, it could get fun here 🙂🙂🙂Yes it is allowed to hope, and the graph shows enormous upside if they hit on the development of medicines. That is also the reason why the shares are priced low now, because it is not certain that they hit. But like you I hope this hits and reaches the same heights as moderna:)
- ·6.11. · MuokattuWorth bringing up this Finansavisen article from last week again: "Healthcare stocks become investors' anti-AI bet". Nervous investors are seeking refuge in the healthcare sector. With the sharp fall we are now seeing in the AI and tech sector in the US, this article becomes extra interesting. When AI and tech stocks lose momentum, we can see a rotation where investors to a greater extent seek towards other sectors – and not least healthcare and biotechnology. The article is already showing signs of this development. American healthcare funds have attracted around 4 billion dollars over 65 trading days, while technology funds in the same period have had outflows of around 6 billion dollars. Healthcare has long stood somewhat in the shadow of the AI hype. Perhaps now is the sector gets its long-awaited renaissance? It would at least be fitting if Nykode also got some of this attention! 😉 https://www.finansavisen.no/helse/2026/10/27/8390924/helseaksjer-blir-investorenes-anti-ai-veddemalGood to keep in mind that teq stocks have risen 100-200% in a short time, which has helped the market upwards in other sectors. When and if margin calls start to hurt in teq, the rest of the market is used as an ATM, meaning that stocks are sold where they necessarily do not want to sell but have to! Pharma is strongly represented there. The first to go are bets (bioteq where it is not clarified), then the safe havens. I am not saying that nykode is one of them, but one should have a portion of risk management in these times.
- 5.11.Nykode Therapeutics to Participate in Fireside Chat at the Guggenheim 3rd Annual Healthcare Innovation Conference https://newsweb.oslobors.no/message/685712Hoping representatives from Eli Lilly are also there and buy the whole joint for kr 10 per share. Allowed to dream 🤭
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 2 908 | ||
| 2 876 | ||
| 3 675 | ||
| 7 946 | ||
| 42 054 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
76 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
1,00 NOK/osake
Viimeisin osinko
33,44%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·4 min sitten · MuokattuModerna continues to rise! 🚀 Yesterday the stock rose 5.83 %, it continues up in the pre-market today, and is now up a whopping 21.81 % the last week. Looking back three months, the increase is an incredible 354.62 %! The market is clearly positioning itself ahead of what could be a very important update. Thursday November 12, Moderna is holding its long-discussed R&D Day, where management is expected to present new, important data and updated timelines for the company's future pipeline. We surely all remember what happened last time Moderna came with a major update to the market? 😉 Could it be set for new movements in the biotech sector? And perhaps worth paying a little extra attention to what this could mean for companies like Nykode? Much exciting happening in the sector right now. And speaking of exciting days in biotech: Nykode is actually also participating at Guggenheim Securities 3rd Annual Healthcare Innovation Conference today! There they will present the company's progress and discuss key value drivers, among others abi-suva, VB10.NEO and the company's immunological tolerance platform. So it is more than just a general investor conference. Management will speak concretely about progress and value drivers.
- ·2 t sittenI advise everyone to opt out of share lending. 1. Log in to Nordnet. 2. Click on Menu. 3. Select My Pages. 4. Open Settings. 5. Find Share Lending (Share Lending). 6. Click End participation / Deactivate share lending. 7. Confirm with BankID if prompted. 8. Verify that the status shows Not active or Not participant. If Share Lending is not found in the menu, you are likely not participating in the scheme.
- ·21 t sittenJust for fun, laying in the charts for Nykode, Nanexa and Moderna, all with 3 years development. If Nykode follows, it could get fun here 🙂🙂🙂Yes it is allowed to hope, and the graph shows enormous upside if they hit on the development of medicines. That is also the reason why the shares are priced low now, because it is not certain that they hit. But like you I hope this hits and reaches the same heights as moderna:)
- ·6.11. · MuokattuWorth bringing up this Finansavisen article from last week again: "Healthcare stocks become investors' anti-AI bet". Nervous investors are seeking refuge in the healthcare sector. With the sharp fall we are now seeing in the AI and tech sector in the US, this article becomes extra interesting. When AI and tech stocks lose momentum, we can see a rotation where investors to a greater extent seek towards other sectors – and not least healthcare and biotechnology. The article is already showing signs of this development. American healthcare funds have attracted around 4 billion dollars over 65 trading days, while technology funds in the same period have had outflows of around 6 billion dollars. Healthcare has long stood somewhat in the shadow of the AI hype. Perhaps now is the sector gets its long-awaited renaissance? It would at least be fitting if Nykode also got some of this attention! 😉 https://www.finansavisen.no/helse/2026/10/27/8390924/helseaksjer-blir-investorenes-anti-ai-veddemalGood to keep in mind that teq stocks have risen 100-200% in a short time, which has helped the market upwards in other sectors. When and if margin calls start to hurt in teq, the rest of the market is used as an ATM, meaning that stocks are sold where they necessarily do not want to sell but have to! Pharma is strongly represented there. The first to go are bets (bioteq where it is not clarified), then the safe havens. I am not saying that nykode is one of them, but one should have a portion of risk management in these times.
- 5.11.Nykode Therapeutics to Participate in Fireside Chat at the Guggenheim 3rd Annual Healthcare Innovation Conference https://newsweb.oslobors.no/message/685712Hoping representatives from Eli Lilly are also there and buy the whole joint for kr 10 per share. Allowed to dream 🤭
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 2 908 | ||
| 2 876 | ||
| 3 675 | ||
| 7 946 | ||
| 42 054 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt